Type 2 diabetes is a heterogeneous disorder of glucose metabolism characterized by insulin resistance, beta-cell dysfunction, and increased glucose production by the liver. According to data from the WHO and the International Diabetes Federation (IDF, 2003) there are about 150 million persons worldwide suffering from diabetes. Diabetes is rapidly increasing and expected to exceed 333 million by 2025 making diabetes fated to become one of the world most important and costly diseases. Current therapies fail to address the underlying pathophysiology of diabetes, and consequently fail to restore normal control of glucose metabolism. Work at the centre aims to further our understanding of factors controlling beta-cell mass regulation and beta cell apoptosis, with the hope of identifying drug targets that can be further developed for therapeutical intervention
- CSM Researchers and collaborators discover predictive biomarker for key colorectal cancer drug
- MSc students from the Netherlands visit the CSM
- Our miRNAmeConverter package (https://bit.ly/2fFe5BA) now supports miRBase 22!
- PurinesDX conference April 24th RCSI
- ‘Breast-Predict’ have developed a tool that may predict how effective chemotherapy is likely to be in treating triple-negative breast cancer patients.
- GLIOTRAIN : European Training Network PhD Student Position available
- CoEN Award to CSM-Network of Centres of Excellence in Neurodegeneration
- GLIOTRAIN, Brain Tumor Ireland and RCSI Presents Two Public Lectures- Friday March 9th
- Physiology News Letter 2nd Edition January 2018
- JPND fund the CSM and its partners 1.5M